60206-95-3

Upstream product

• 61764-41-8 2-methyl-1,1,4-trioxo-1,2,3,4-tetrahydro-1λ⁶-naphtho[2,1-e][1,2]thiazine-3-carboxylic acid ethyl ester 
• 62-53-3 aniline 
• 60206-83-9 2-methyl-1,1,4-trioxo-1,2,3,4-tetrahydro-1λ⁶-naphtho[2,1-e][1,2]thiazine-3-carboxylic acid methyl ester 
• 234-45-7 naphtho[2,1-d]isothiazole 
• 61764-42-9 (1,1,3-trioxo-1,3-dihydro-1λ⁶-naphtho[2,1-d]isothiazol-2-yl)-acetic acid ethyl ester 
• 60206-97-5 2-methyl-1,1-dioxo-2,3-dihydro-1H-1λ⁶-naphtho[2,1-e][1,2]thiazin-4-one 
• 103-71-9 phenyl isocyanate 
• 60207-05-8 2-methyl-1,1-dioxo-4-pyrrolidin-1-yl-1,2-dihydro-1λ⁶-naphtho[2,1-e][1,2]thiazine-3-carbonyl chloride 
• 60206-94-2 1,1,4-trioxo-1,2,3,4-tetrahydro-1λ⁶-naphtho[2,1-e][1,2]thiazine-3-carboxylic acid anilide 
• 74-88-4 methyl iodide 
• 61764-43-0 1,1,4-trioxo-1,2,3,4-tetrahydro-1λ⁶-naphtho[2,1-e][1,2]thiazine-3-carboxylic acid ethyl ester 
• 60206-86-2 (1,1,3-trioxo-1,3-dihydro-1λ⁶-naphtho[2,1-d]isothiazol-2-yl)-acetic acid methyl ester 
• 60206-87-3 1,1,4-trioxo-1,2,3,4-tetrahydro-1λ⁶-naphtho[2,1-e][1,2]thiazine-3-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity

Meloxicam (5), an NSAID in the enol-carboxamide class, was developed on the basis of its antiinflammatory activity and relative safety in animal models. In subsequent screening in microsomal assays using human COX-1 and COX-2, we discovered that it possessed a selectivity profile for COX-2 superior to piroxicam and other marketed NSAIDs. We therefore embarked on a study of enol-carboxamide type compounds to determine if COX-2 selectivity and potency could be dramatically improved by structural modification. Substitution at the 6- and 7-positions of the 4-oxo-1,2-benzothiazine-3- carboxamide, alteration of the N-methyl substituent, and amide modification were all examined. In addition we explored several related systems including the isomeric 3-oxo-1,2-benzothiazine-4-carboxamides, thienothiazines, indolothiazines, benzothienothiazines, naphthothiazines, and 1,3- and 1,4- dioxoisoquinolines. While a few examples were found with greater potency in the COX-2 assay, no compound tested had a better COX-2/COX-1 selectivity profile than that of 5.

4-Hydroxy-2H-naphtho[2,1-e]-1,2-thiazine-3-carboxamide-1,1-dioxides and salts thereof

Compounds of the formula SPC1 Wherein R1 is hydrogen, methyl or ethyl, and Ar is phenyl, 3-chlorophenyl, 3-bromophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3-tolyl, 2-methoxyphenyl, 3-methoxyphenyl, 2-pyridyl, 4-methyl-2-pyridyl, 6-methyl-2-pyridyl, 3-hydroxy-2-pyridyl, 3-pyridyl, 4-pyridyl, 6-chloro-3-pyridazinyl, 2-pyrazinyl, 6-chloro-2-pyrazinyl, 6-chloro-4-pyrimidinyl, 2-thiazolyl, 4-methyl-2-thiazolyl, 4-ethyl-2-thiazolyl, 5-methyl-2-thiazolyl, 5-ethyl-2-thiazolyl, 4,5-dimethyl-2-thiazolyl, 4-ethyl-5-methyl-2-thiazolyl, 5-ethyl-4-methyl-2-thiazolyl, 2-benzothiazolyl, 4,5,6,7-tetrahydro-2-benzothiazolyl, 5,6-dihydro-7H-thiopyrano[4,3-d]thiazol-2-yl, 3-methyl-5-isothiazolyl, 1,3,4-thiadiazolyl, 5-methyl-1,3,4-thiadiazol-2-yl or 5-methyl-3-isoxazolyl, And non-toxic, pharmacologically acceptable salts thereof formed with an inorganic or organic base; the compounds as well as their salts are useful as inhibitors of platelet adhesion and aggregation.